IL215549A0 - Pseudomonas aeruginosa antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa - Google Patents
Pseudomonas aeruginosa antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosaInfo
- Publication number
- IL215549A0 IL215549A0 IL215549A IL21554911A IL215549A0 IL 215549 A0 IL215549 A0 IL 215549A0 IL 215549 A IL215549 A IL 215549A IL 21554911 A IL21554911 A IL 21554911A IL 215549 A0 IL215549 A0 IL 215549A0
- Authority
- IL
- Israel
- Prior art keywords
- pseudomonas aeruginosa
- lipopolysaccarides
- lps
- antibody specific
- serotype iats
- Prior art date
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 title 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005245 | 2009-04-09 | ||
| PCT/EP2010/002158 WO2010115606A1 (en) | 2009-04-09 | 2010-04-06 | Human monoclonal antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL215549A0 true IL215549A0 (en) | 2011-12-29 |
Family
ID=40934847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215549A IL215549A0 (en) | 2009-04-09 | 2011-10-05 | Pseudomonas aeruginosa antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120114657A1 (enExample) |
| EP (1) | EP2417157A1 (enExample) |
| JP (1) | JP2012523221A (enExample) |
| KR (1) | KR20120016086A (enExample) |
| CN (1) | CN102639562A (enExample) |
| BR (1) | BRPI1013427A2 (enExample) |
| CA (1) | CA2758081A1 (enExample) |
| IL (1) | IL215549A0 (enExample) |
| MX (1) | MX2011010634A (enExample) |
| WO (1) | WO2010115606A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130004499A1 (en) * | 2010-02-18 | 2013-01-03 | Symphogen A/S | Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa |
| JP6058645B2 (ja) * | 2011-06-10 | 2017-01-11 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用 |
| PT2776065T (pt) | 2011-11-07 | 2020-09-25 | Medimmune Ltd | Terapias de combinação que usam moléculas de ligação de psl e pcrv anti-pseudomonas |
| AU2016353073A1 (en) | 2015-11-10 | 2018-06-07 | Visterra, Inc. | Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof |
| WO2018136626A1 (en) | 2017-01-18 | 2018-07-26 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
| US11969476B2 (en) | 2020-04-03 | 2024-04-30 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4834975A (en) | 1984-05-25 | 1989-05-30 | Genetics Corporation | Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production |
| US5955584A (en) * | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| DE60331292D1 (de) * | 2003-05-14 | 2010-04-01 | Kenta Biotech Ag | Humaner monoklonaler Antikörper spezifisch für Lipopolysacchariden (LPS) des Serotyps IATS O6 von Pseudomonas aeruginosa |
| EP1690875A1 (en) * | 2005-02-14 | 2006-08-16 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype |
-
2010
- 2010-04-06 EP EP10713132A patent/EP2417157A1/en not_active Ceased
- 2010-04-06 CA CA2758081A patent/CA2758081A1/en not_active Abandoned
- 2010-04-06 CN CN2010800256287A patent/CN102639562A/zh active Pending
- 2010-04-06 KR KR1020117026384A patent/KR20120016086A/ko not_active Withdrawn
- 2010-04-06 WO PCT/EP2010/002158 patent/WO2010115606A1/en not_active Ceased
- 2010-04-06 US US13/262,791 patent/US20120114657A1/en not_active Abandoned
- 2010-04-06 MX MX2011010634A patent/MX2011010634A/es not_active Application Discontinuation
- 2010-04-06 JP JP2012503917A patent/JP2012523221A/ja not_active Withdrawn
- 2010-04-06 BR BRPI1013427A patent/BRPI1013427A2/pt not_active IP Right Cessation
-
2011
- 2011-10-05 IL IL215549A patent/IL215549A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120016086A (ko) | 2012-02-22 |
| EP2417157A1 (en) | 2012-02-15 |
| US20120114657A1 (en) | 2012-05-10 |
| JP2012523221A (ja) | 2012-10-04 |
| CA2758081A1 (en) | 2010-10-14 |
| WO2010115606A1 (en) | 2010-10-14 |
| CN102639562A (zh) | 2012-08-15 |
| BRPI1013427A2 (pt) | 2016-04-05 |
| MX2011010634A (es) | 2012-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276622A (en) | Antibody formulation | |
| ZA201003852B (en) | Antibodies to the pcrv of pseudomonas aeruginosa | |
| IL228988A (en) | Antibody preparations for the treatment of vaccine-related diseases | |
| CR10823A (es) | Formulacion parenteral de anticuerpos abeta | |
| IL211190A0 (en) | Novel antibody formulation | |
| PT2170390T (pt) | Formulações com anticorpo natalizumab | |
| AU2013207589A1 (en) | Anti-Siglec-15 Antibody | |
| EP2512502A4 (en) | METHOD AND COMPOSITIONS FOR REMOVING TUMORS | |
| EP1987064A4 (en) | DOMAIN ANTIBODY CONSTRUCT | |
| EP2536835A4 (en) | ANTIBODIES TO SEROTYPE G-LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA | |
| BRPI1011805A2 (pt) | anticorpos anti incisura-1 | |
| SI2185543T1 (sl) | Postopek za optiäśno loäśevanje soli omeprazola | |
| IL215549A0 (en) | Pseudomonas aeruginosa antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa | |
| PL2248826T3 (pl) | Przeciwciało skierowane przeciwko PcrV | |
| EP2454734B8 (de) | Anordnung zur videoaufnahme von veranstaltungen | |
| EP2318436A4 (en) | ANTIBODIES OF DIFFERENT DOMAINS | |
| PL2252444T3 (pl) | Urządzenie do wytwarzania okładzin ciernych | |
| NO20081856L (no) | Anordning ved rensemagnet | |
| EP2499125A4 (en) | PROCESS FOR DEDOLLING OMEPRAZOLE | |
| EP2236515A4 (en) | COMPONENT PROTEIN PA1698 FOR PSEUDOMONAS AERUGINOSA TYPE-III SECRETION SYSTEM | |
| EP2523562A4 (en) | NICOTINE acetylcholine receptor Antagonist | |
| AU2022203585B2 (en) | Modified antibody constant region | |
| AU2008904178A0 (en) | Anti-IL-12/23 Antibodies | |
| AU2009902142A0 (en) | Variant domain antibodies | |
| AU2009905855A0 (en) | The new technique for cleaning pipelines |